Abstract. The neuronal protein ␣-synuclein has been implicated in the pathogenesis of Parkinson disease and other neurodegenerative diseases. Although many studies report that ␣-synuclein expression is restricted to neuronal presynaptic terminals, this protein aggregates in Lewy bodies in somata that are typically distant from their axon terminals. Few studies have addressed this paradox and there has been no compelling explanation proposed for the apparent discrepancy between the locus of neuronal ␣-synuclein expression and the loci of Lewy bodies in the majority of Parkinson disease cases. We explored this issue by extensively characterizing the monoclonal antibody Synuclein-1 (Syn-1) and using this highly selective antibody to map the distribution of ␣-synuclein throughout rat brain and in human substantia nigra (SN). Additionally, ␣-synuclein expression in rat SN detected by 2 polyclonal antibodies against ␣-synuclein was compared with that detected by the Syn-1 antibody. In contrast with many previous reports, ␣-synuclein was detected by Syn-1 in neuronal somata and dendrites in restricted brain regions, as well as more ubiquitously in axons and terminals. The strongest ␣-synuclein neuronal expression in rat was found in brainstem and cortical regions that are homologous to regions prone to Lewy body formation in humans. The Syn-1 antibody labeled abundant somatodendritic ␣-synuclein in both rat and human SN, a major locus of Lewy body formation and neurodegeneration in Parkinson disease. By contrast, very few immunoreactive somata in the rat SN were labeled by the 2 polyclonal antibodies. We explore possible explanations for the differences in conflicting reports of patterns of ␣-synuclein expression in brain, including differences among antibodies.
INTRODUCTION
The neuronal protein ␣-synuclein has been implicated increasingly in the pathogenesis of Parkinson disease (PD) and other neurodegenerative diseases. Point mutations in the ␣-synuclein gene have been identified in 2 rare familial forms of PD (1, 2) . Likewise, transfections of the human wild type gene in both Drosophila and mouse produce some characteristics of PD (3, 4) . Moreover, immunohistochemistry and electron microscopy studies have identified ␣-synuclein as the major component of Lewy bodies in the sporadic form of PD (5) (6) (7) (8) and in the neuronal inclusions of other synucleinopathies (9) (10) (11) (12) (13) (14) (15) (16) (17) .
Synucleins comprise a family of small, highly conserved proteins, especially abundant in neurons. In PD and cortical Lewy body dementia (LBD), Lewy bodies are located in the cytoplasm of neuronal somata in susceptible brain regions (18) (19) (20) (21) . Paradoxically, however, many studies report that ␣-synuclein expression is restricted to cytoplasm of presynaptic terminals in nondiseased mammalian brain (9, (22) (23) (24) (25) (26) . Little attention has been paid to the apparent discrepancy between the restriction of Lewy bodies to somata and the putative absence of ␣-synuclein in these neuronal compartments. This disparity is especially evident in the brainstem regions that undergo severe degeneration in PD (21, 22, 27) , such as the substantia nigra (SN) and locus ceruleus, both of which in human brain project to targets as far as several centimeters from the neuronal somata. The finding that the Ala30Pro mutant protein shows a marked decrease in lipid affinity led to the proposal that this form of ␣-synuclein fails to be properly transported to the synapse by axonal transport, and thus accumulates in neuronal cell bodies in this familial form of PD (28) . This putative failure of anterograde axonal transport in the rare A30P genotype, however, does not account for the neuronal locus of Lewy body formation in the majority of PD cases.
In previous work, we found evidence of nuclear and membrane binding of ␣-synuclein, as well as its presence in cytoplasm of cultured dopaminergic cells (29) . Recently, there have been a few reports of somal localization of ␣-synuclein in brain (17, (30) (31) (32) in addition to the axonal presence commonly reported. To explore this issue in more detail, we mapped the expression of ␣-synuclein throughout the normal rat brain and human midbrain and described its subcellular distribution using a highly selective monoclonal antibody (mAB) against ␣-synuclein, Syn-1. We now report that Syn-1 mapping in rat brain reveals widespread expression of ␣-synuclein in axon fibers and terminals and a more restricted pattern of somal and dendritic expression. Furthermore, the distribution of ␣-synuclein-positive neuronal somata reveals a striking overlap with homologous neuronal populations in human brain vulnerable to Lewy body formation in PD and cortical LBD.
MATERIALS AND METHODS

Tissue
All animal experiments were performed according to the National Institute of Health Guide for the Care and Use of Laboratory Animals. Four adult male Sprague Dawley rats (Taconic, Germantown, NY) weighing approximately 200 g were deeply anesthetized with an overdose of sodium pentobarbital and transcardially perfused with saline, followed by 4% paraformaldehyde in 0.1 M phosphate buffered saline (PBS). Brains were maintained at 4ЊC for postfixation in 4% paraformaldehyde/PBS overnight, followed by immersion in 0.1 M PBS (pH 7.4) containing 20% sucrose for 48 hours, then rapidly frozen in isopentane cooled on dry ice and stored at Ϫ75ЊC. Human brain tissue, which was harvested 10 hours postmortem from a 63-year-old, nondiseased Caucasian male was obtained from the University of Miami Brain Endowment Bank for examination of ␣-synuclein expression in normal human SN. The SN was dissected and rapidly frozen in isopentane. While frozen, the tissue was immersion fixed in 4% paraformaldehyde in PBS for 12 hours. Following fixation, the tissue was transferred to 0.1 M PBS containing 20% sucrose for 48 hours at 4ЊC. The tissue was then refrozen by transfer to precooled isopentane and stored at Ϫ70ЊC until sectioned by cryostat.
Antibodies and Immunogens
The antibodies used were Syn-1 mouse anti-rat mAB (BD Transduction Laboratories, Lexington, KY); goat anti-human ␣-synuclein pAB (Santa Cruz Biotechnology, Inc., Santa Cruz, CA); and rabbit anti-human ␣-synuclein pAB (US Biological, Swampscott, MA). All 3 antibodies recognize human, rat, and mouse ␣-synuclein. Blocking immunogens for Syn-1 and the rabbit pAB were ␣-synuclein 15-123 and ␣-synuclein 116-131, respectively. The immunogen for the goat pAB includes approximately 20 amino acids of the C-terminus of ␣-synuclein and its exact sequence is proprietary information of Santa Cruz Biotechnology, Inc. The dilutions for each antibody were chosen to be a concentration at which ␣-synuclein protein staining was maximized without the appearance of nonselective binding as detected by the negative tissue control procedures that were done for each of the antibodies.
Histology
Coronal serial sections (30 m) through the whole rat brain and human SN were cut with a cryostat. Sections processed for ␣-synuclein immunohistochemistry were incubated free-floating for 3 days at 4ЊC in 0.01 M PBS containing the mouse anti-rat Syn-1 mAB (1:3,000) or the goat anti-human pAB (1:1,000), 1% normal horse serum (Vector Laboratories, Burlingame, CA) and 0.3% Triton X-100 (Sigma, St. Louis, MO) or containing the rabbit anti-human ␣-synuclein pAB (1:50), 1% normal goat serum and 0.3% Triton X-100. After 3 washes, sections were incubated with their respective secondary antibodies (1:1,000, Vector Laboratories) for 90 min as described above. The product of the antibody immunoreaction was then developed according to the avidin biotin complex method with the Vectastain elite ABC kit (Vector Laboratories) prior to mounting sections on gelatin-coated slides. The chromogen used for the rat brain sections was diaminobenzidine (DAB); whereas Vector blue (Vector Laboratories) was used for the human SN sections to distinguish clearly between ␣-synuclein immunoreactivity and neuromelanin.
Syn-1 was used to map the distribution of ␣-synuclein throughout the rat brain and in the human SN. Except as noted, ␣-synuclein immunoreactivity refers to that detected by Syn-1. The 2 pABs were used to compare ␣-synuclein labeling in rat midbrain at the level of SN. Immunoreactivity was assessed by 2 raters (GA and MCB) using a semiquantitative rating of absent (Ϫ), or mild, to very strong (ϩ-ϩϩϩϩϩ) (Table) .
Controls
For negative controls, representative sections were processed for immunoreactivity with the following alterations of procedure: 1) omission of the primary antibody; 2) omission of the secondary antibody; 3) substitution of serum IgGs for the primary antibody; and 4) preincubation of each antibody with its respective immunogen prior to tissue incubation.
In addition to the aforementioned controls, the selectivity and sensitivity of the Syn-1 mAB was rigorously characterized by additional positive control tissue studies, which consisted of preincubation of the Syn-1 mAB with an excess of recombinant ␤-or ␥-synuclein prior to immunostaining. Furthermore, the specificity of Syn-1 for ␣-synuclein was assessed in vitro in comparison with the ␤-or ␥-isoforms of synuclein using Western immunoblot and enzyme-linked immunoabsorbent assay (ELISA). Quantities of 1, 5, and 10 g of recombinant ␤-and ␥-synuclein protein (generous gift of Dr. J. George) and recombinant GST-fusion ␣-synuclein protein (generous gift of Dr. M. Wilson) were dissolved in SDS sample buffer (Novex, Carlsbad, CA), loaded onto lanes of 4% to 20% linear gradient TrisGlycine mini gels, and subjected to electrophoresis (applied constant voltage, 125V). Each gel was then placed on a PVDF membrane (Invitrogen, Carlsbad, CA), immersed in transfer buffer (Novex), and transferred to the membrane by the application of 25V for 2 hours. After the transfer was completed, the PVDF membrane was soaked in blocking buffer for 1 hour, incubated for 1 hour with the Syn-1 mAB (1:500 dilution in 0.1% TPBS), washed 3 times for 20 min each time in 0.1% TPBS, incubated for 1 hour in secondary antibody (anti-mouse horseradish peroxidase, BD Transduction Laboratories, 1:2,000 dilution in 0.1% TPBS), then washed again 3 times as before. The reactive bands were visualized by chemiluminescence (ECL; Amersham, Piscataway, NJ) (Fig. 1) . For the ELISA, each well was plated with 1 g of 1 of the recombinant isoforms of synuclein (␣, ␤, or ␥), and then probed with dilutions of Syn-1 mAB ranging from 1 to 0.01 g/ml (1:250-1:32,000 dilution) (Fig. 2) .
Finally, the specificity of the Syn-1 mAB ␣-synuclein was assessed in rat brain lysate. Rat brain tissue was homogenized and lysed by sonification in 8 M urea lysis buffer, and then Immunohistochemical staining of ␣-synuclein on 30 M coronal rat brain sections was performed using the specific Syn-1 mAB. Immunoreactivity detected was rated Ϫ (no staining) to ϩϩϩϩϩ (very intense staining) by 2 raters (GA and MCB). Presence of Lewy body in the various brain areas is described in references 9, 22, 36, 43, 44 and 52-62. Presence ranged from Ϫ (absent) to ϩϩϩϩϩ (consistently found in very high amounts). NA ϭ non-applicable. A blank cell in the table indicates that the presence of Lewy bodies has not been described in that brain area.
samples were subjected to gel electrophoresis followed by Western immunoblot, as described above (Fig. 3) .
RESULTS
Characterization of Antibodies
The sensitivity and specificity of Syn-1 for ␣-synuclein was confirmed through numerous control experiments. For purposes of comparison with the pattern identified by the Syn-1 antibody, ␣-synuclein expression in rat midbrain at the level of the SN was examined using 2 polyclonal antibodies. For each antibody tested, elimination of either the primary or the secondary antibody completely abolished immunoreactivity, as did the substitution of IgGs for the primary antibody and the preincubation of each antibody with its immunogen prior to tissue incubation. Therefore, the staining could not be attributed to nonspecific binding.
The Syn-1 mAB was used to map the distribution of ␣-synuclein expression throughout rat brain and in human SN, and was therefore extensively and rigorously characterized. Neither ␤-nor ␥-synuclein preincubation of Syn-1 abolished the pattern of staining in brain tissue, demonstrating that there was no significant Syn-1 immunohistochemical cross-reactivity with either of these synuclein isoforms. Similarly, in Western immunoblot, Syn-1 produced an intense reaction with 1 to 10 g of recombinant GST-fusion ␣-synuclein, but was undetectable when used to probe the same amounts of ␤-and ␥-synuclein isoforms (Fig. 1) . In ELISA, the Syn-1 mAB (1:250 to 1:32,000) reaction product showed linear concentration reactivity with ␣-synuclein, but did not crossreact with the ␤-or ␥-synuclein isoforms at any dilution (Fig. 2) . Finally, in the rat brain lysate extracted under stringent denaturing/reducing conditions, a single band was observed at a molecular weight of approximately 17 kDa, which corresponds to the migration level of the ␣-synuclein monomer (Fig. 3) .
Immunohistochemistry
The 2 . ELISA analysis of the Syn-1 antibody reactivity with synuclein isoforms. Each well was plated with 1 g of one of the recombinant isoforms of synuclein (␣, ␤, or ␥), and then probed with dilutions of Syn-1 mAB ranging from 1 to 0.01 g/ml (1:250 to 1:32,000 dilution). Syn-1 shows strong binding to ␣-synuclein but no detectible cross-reactivity with the ␤-and ␥-isoform. Fig. 3 . Western blot analysis of the Syn-1 antibody reactivity with rat brain lysate. Tris-glycine gel lanes were loaded with 10 g of brain lysate and the blot was probed with Syn-1 at a dilution of 1:500. The Syn-1 antibody shows a band at a migration level of 17 kDa, which is consistent with the migration level of the ␣-synuclein monomer.
Table also summarizes the regional distribution of Lewy bodies in human pathologies based upon an extensive literature review and citations of these reports appear in the Table legend .
Neocortex
Moderate to strong ␣-synuclein immunoreactivity was detected in axonal processes and terminals throughout all fields and in all layers of the neocortex. In contrast, somata and dendrites showed a highly restrictive regional and laminar pattern of ␣-synuclein staining. In frontoparietal sensory and motor cortex overlying striatum and extending medially into cingulate cortex, ␣-synuclein staining was detected in cell layer V and deep layer VI (Fig. 4A, B) . This pattern of laminar staining was observed throughout the anterior to posterior extent of cortex overlying the striatum. Deep layer VI but not layer V contained ␣-synuclein-immunopositive neurons posterior to the striatum, continuing to the caudal-most extent of the corpus callosum. These cells resembled in size and distribution pattern glial fibrillary acidic protein (GFAP)-positive cells overlying corpus callosum, suggesting that they might be glia.
Midbrain
The SN pars compacta (SNc) contained many large somata and dendrites that stained intensely positive for ␣-synuclein, as well as thinner fibers presumed to be axons. The cell-poor SN pars reticulata (SNr) contained dense ␣-synuclein-positive fibers but few immunopositive neuronal cell bodies (Fig. 5A, B) . The larger processes appear to be the dendrites of inverted neurons of the ventral-most layer of SNc, which project into SNr (33) , while the presence of immunoreactive smaller fibers suggests the projection of ␣-synuclein-positive axons into SNr, as well.
Considerable variability in the pattern of ␣-synuclein expression in midbrain was observed among the antibodies. The pattern of cellular immunoreactivity in rat midbrain detected by the 2 pABs (Fig. 5C-F that of Syn-1. Very few somata were labeled for ␣-synuclein in SNc by either of the pABs. The rabbit pAB labeled some perikarya in the ventromedial tier of SNc (Fig. 5C, D) , whereas the goat pAB stained a few somata in the lateral tier (Fig. 5E, F) . Similar to the Syn-1 mAB, both ␣-synuclein pABs labeled the neuropil of SNc and SNr. Overall, staining was less intense with the pABs than with the Syn-1 mAB.
In human SN, the pattern of ␣-synuclein immunoreactivity detected by Syn-1 was very similar to that in the rat (Fig. 5G, H) . Prominent perikaryal expression of ␣-synuclein was observed in the human neuromelanin-containing neurons of SNc. In addition, strong punctuate staining of the SNc was detected, consistent with terminal labeling of ␣-synuclein. Abundant fibers, but few cell bodies, were labeled in the SNr.
Basal Ganglia
The striatum and globus pallidus (major projection targets of the SNc) contained abundant, strongly stained processes but were striking for their absence of somal staining: not a single neuronal cell body within striatum was identified as containing ␣-synuclein (Fig. 6A, B) . This finding indicates that the striatum has no intrinsic cells expressing ␣-synuclein but is the target of numerous ␣-synuclein containing projection neurons. Both SNc and layer V of sensorimotor cortex contained many ␣-synuclein-positive neurons and project widely to striatum (33) (34) (35) .
The pattern in the mesolimbic dopamine pathway paralleled that of the nigrostriatal system. Similar to the SNc, the ventral tegmental area (VTA) contained large neurons that were intensely immunoreactive for ␣-synuclein (Fig.   5A ), while its major target, the nucleus accumbens, contained immunoreactive fibers but lacked staining in the somata. Thus, the nucleus accumbens, like the striatum, contained ␣-synuclein-positive axons and terminals but no intrinsic neuronal expression. The pattern of axon and terminal ␣-synuclein staining and absence of intrinsic neuronal expression was evident for other basal ganglia structures, such as the ventral pallidum and the subthalamic nucleus.
Entorhinal Cortex and Hippocampus
Extensive ␣-synuclein staining was found in neuronal cell bodies as well as fibers throughout entorhinal cortex, the major source of hippocampal afferents. Consistent with this, processes in the anterior Ammon's horn strata (i.e. stratum oriens, stratum radiatum, and stratum lacunosum moleculare) stained moderately to strongly for ␣-synuclein (Fig. 7A) . In contrast, the expression of ␣-synuclein in neuronal cell somata varied greatly across the anterior to posterior extent of hippocampus. In the dorsal hippocampus, granule cells in dentate gyrus contained ␣-synuclein, while the pyramidal neuronal layers of CA1, CA2, and CA3bc were devoid of staining (Fig. 7A, B ). There were, however, some ␣-synuclein-positive neurons in CA3a. This pattern was altered toward the ventral and caudal extent of hippocampus (retrohippocampus). In retrohippocampus, ␣-synuclein was detected in the pyramidal cell layers, in addition to being present in the dentate granule neurons (Fig. 8A) . Many neurons of the subiculum, the major efferent target of the hippocampus, contained ␣-synuclein in somata (Fig. 8B) . (A, B, G, H) , rabbit pAB (C, D), and goat pAB (E, F). The chromogen used for the rat brain sections was diaminobenzidine (DAB), whereas Vector blue (Vector Laboratories) was used for the human SN sections to distinguish clearly between ␣-synuclein immunoreactivity and neuromelanin. Arrow in panel (H) points to Vector blue staining of ␣-synuclein in perikaryon of human SNc, which is distinct from the light brown neuromelanin pigment in the magnified inset of panel (G). Dense somal staining was observed with the Syn-1 mAB in both rat and human SNc and VTA. Sporadic somal staining was detected in rat human SNc and VTA with the ␣-synuclein pABs. Original magnifications: A, C, E, ϫ50; G, ϫ100; B, D, F, ϫ400; H, ϫ630. 
Piriform Cortex and the Amygdala Complex
␣-Synuclein was concentrated in olfactory-related brain regions in neurons as well as fibers. Many neurons in piriform cortical layers II and III (Fig. 9 ) and the olfactory tubercle contained ␣-synuclein immunoreactivity. The amygdala, a major projection target of piriform cortex, contained abundant ␣-synuclein-positive fibers and terminals in all nuclei. The amygdala receives projections from numerous other regions containing ␣-synuclein-positive neurons including olfactory bulb, nucleus of the lateral olfactory tract, entorhinal cortex, various thalamic and hypothalamic nuclei, diagonal band, and the brainstem monoaminergic nuclei (36, 37) . The content of ␣-synuclein in neuronal cell bodies of amygdala nuclei was variable. With respect to neuronal cell somata, the olfactory-related nuclei of amygdala, which are continuous with and extend from piriform cortex to form the outer 12 . ␣-Synuclein immunoreactivity in the rat basal cholinergic forebrain system using the Syn-1 antibody. Neurons throughout the cholinergic forebrain system were immunoreactive for ␣-synuclein, but fiber staining was very weak in these structures. Original magnification: ϫ200. Scale bar: 50 m. Abbreviation: VDBD ϭ nucleus of the vertical limb of the diagonal band. Fig. 13 . ␣-Synuclein immunoreactivity in the rat habenula using the Syn-1 antibody. ␣-Synuclein immunoreactivity was very strong in the neuronal cell bodies of the medial habenula while in the lateral part of the habenula ␣-synuclein staining was virtually absent. Original magnification: ϫ200. Scale bar: 50 m. Abbreviations: Mhb ϭ medial habenula; Lhb ϭ lateral habenula. most nuclei of amygdala, had strongest ␣-synuclein neuronal expression. Thus, the piriform-amygdala transition area and the cortical, medial, and central nuclei (Fig. 10 ) contained many intensely positive neurons. As in hippocampus, there was an anterior-to-posterior gradient in neuronal expression in amygdala, with more ␣-synucleinpositive neurons detected in the posterior regions of several nuclei. The medial amygdaloid nucleus provides a clear example of this gradient, with sparse ␣-synucleinpositive neurons in the anterior extent, in contrast with many intensely stained neurons toward the posterior. The cells of the basomedial, basolateral, and lateral nuclei were only weakly immunoreactive for ␣-synuclein. The strongest ␣-synuclein neuronal expression within the amygdala complex was seen in the amygdala-hippocampal area (Fig. 11A, B) . Numerous ␣-synuclein-positive somata, fibers, and terminals were evident in this region. The bed nucleus of the stria terminalis, the major target of amygdala efferents, contained abundant fiber staining, while ␣-synuclein was detected only faintly in the somata.
Basal Cholinergic Forebrain
Neurons throughout the basal cholinergic forebrain were immunoreactive for ␣-synuclein, although there was little fiber staining in these structures. The medial septal nucleus and both the vertical and horizontal limbs of the diagonal band contained many intensely ␣-synuclein-positive neurons (Fig. 12) . Throughout the brain, as well as in the cholinergic forebrain, the pattern of ␣-synuclein staining bears a striking resemblance to the pattern of acetylcholinerase staining (38) .
Thalamus ␣-Synuclein content was heterogeneous in the nuclei of the thalamus. There were few somata and sparse fibers containing ␣-synuclein immunoreactivity in many thalamic nuclei, including the anterior, mediodorsal, and ventral complexes. The lateral nuclear complex contained few neuronal cell bodies, but abundant fibers, expressing ␣-synuclein. The midline and intralaminar nuclei contained relatively more abundant ␣-synuclein. In the midline nuclei, neuronal staining was strong in the paraventricular, interanteriomedial, and rhomboid nuclei, but weaker in the paratenial and reuniens nuclei. Neuronal cell bodies within the centromedial nucleus of the intralaminar complex stained intensely for ␣-synuclein, while neurons of the parafascicular, centrolateral, and paracentral nuclei were only faintly immunopositive. Fiber staining throughout the midline and intralaminar complexes was sparse to moderate. A notable contrast was observed within the habenula (Fig. 13) . The medial habenula contained many intensely immunoreactive somata and moderate fiber staining, while the lateral habenula was devoid of ␣-synuclein staining in neuronal cell bodies or fibers. Consistent with this observation, the medial habenula receives cholinergic afferents from medial septal nucleus (39) , which contains ␣-synuclein-positive neurons, and projects to the interpeduncular nucleus in brainstem, which contains ␣-synuclein-positive fibers. Afferents to the lateral habenula are primarily from the lateral preoptic hypothalamic region and the entopeduncular nucleus, neither of which contains ␣-synuclein-positive neurons.
Hypothalamus ␣-Synuclein content also varied among the nuclei of hypothalamus. The preoptic area and the lateral hypothalamic nucleus had virtually no neuronal or fiber staining. The anterior, paraventricular, and ventromedial hypothalamic nuclei contained scattered, moderately immunopositive neurons. The periventricular nucleus was notable for containing a small number of strongly positive neuronal cell bodies. The tuberal magnocellular nucleus contained small clusters of intensely stained large neurons. Similar clusters of ␣-synuclein-positive neurons were found also in the caudal-most extent of arcuate and dorsomedial nuclei (Fig. 14) , but positive neurons were rare in the anterior regions of these nuclei. Presynaptic fibers containing ␣-synuclein were sparse throughout the hypothalamus with the exception of the mammillary complex, which contained a moderate density of fibers expressing ␣-synuclein immunoreactivity but no neuronal staining.
Brainstem
The brainstem nuclei were among the most intensely stained of all brain regions. The central gray had ␣-synuclein-positive neuronal cell bodies and fibers through its entire extent (Fig. 15) . The neurons of the dorsal raphe nucleus stained strongly for ␣-synuclein, but fiber staining was moderate (Fig. 15) . The pontine tegmentum contained many ␣-synuclein-positive neuronal cell bodies and fibers, including dense fiber staining in the trapezoid body. The locus ceruleus had ␣-synuclein-positive large neurons, but weak expression in the smaller neurons. Fiber staining throughout locus ceruleus was dense. Neurons of the dorsal vagal motor (X) nucleus stained intensely for ␣-synuclein, but contained only a moderate concentration of ␣-synuclein-positive fibers (Fig. 16) . Neuronal cell bodies of the pedunculopontine nucleus stained strongly for ␣-synuclein while fibers were only weakly immunoreactive. 
DISCUSSION
The immunohistochemical mapping of rat brain by the Syn-1 mAB revealed a pattern of ␣-synuclein immunoreactivity with cellular expression in discrete populations of neurons, in addition to widespread labeling of axons and terminals throughout the majority of regions. Neurons of the midbrain nuclei SNc and VTA were among the most strongly immunoreactive of all brain regions. By contrast, the striatum and nucleus accumbens, targets of these respective nuclei, contained abundant ␣-synuclein fibers and terminals but were devoid of neuronal staining. This mapping pattern indicates that these structures contain no intrinsic cells expressing ␣-synuclein but are the targets of ␣-synuclein projection neurons. Many brainstem nuclei expressed somal ␣-synuclein. Notably, neurons of the dorsal vagal motor nucleus were intensely ␣-synuclein-positive. Neurons expressing high levels of ␣-synuclein were detected throughout the dorsal raphe, while the locus ceruleus stained strongly for ␣-synuclein in large but not small cells. In cortex, neurons of layer V of frontoparietal and cingulate cortices overlying striatum and deep layer VI somata over the entire extent of corpus callosum were immunoreactive for ␣-synuclein. Piriform and entorhinal cortices contained numerous ␣-synuclein-positive neurons.
Parkinson disease is characterized by neurodegeneration of numerous brainstem and midbrain nuclei. Neurons of SNc, and to a lesser extent those of VTA-but neither striatum nor nucleus accumbens-form Lewy bodies and degenerate in PD (40) (41) (42) . Similarly, neurons of the dorsal vagal motor nucleus, dorsal raphe, and locus ceruleus are sites of Lewy body formation and neurodegeneration (18, 22, 43) . Deep layers of sensorimotor cortex, as well as piriform and entorhinal cortices, are loci of Lewy body formation in PD and cortical LBD (19, 40, 44, 45) . The pattern of Syn-1 immunoreactivity that emerged in rat brain revealed a conspicuous correspondence between the loci of neuronal expression of ␣-synuclein and the homologous structures in human brain susceptible to Lewy body formation. The Syn-1 mapping pattern, in contrast with the pattern indicated by the polyclonal antibodies, suggests that the most parsimonious explanation of the distribution is that these cytoplasmic inclusions form at the locus of the neuronal expression of ␣-synuclein. Other types of ␣-synuclein inclusions have been detected also in other subcellular regions with high ␣-synuclein expression. For example, dystrophic axons containing ␣-synuclein aggregates have been described in regions with abundant axonal ␣-synuclein, such as the hippocampus (46) .
While the population of ␣-synuclein-positive neurons in the rat brain subsumes that of Lewy body-vulnerable neurons in human brain, some regions containing ␣-synuclein-positive neurons are relatively resistant to Lewy body formation. ␣-Synuclein was detected in neurons of medial septal nucleus, diagonal band, and retrohippocampus, although none of these regions are notable for Lewy body formation (40) . The relative resistance of these structures to Lewy body formation, despite high levels of ␣-synuclein expression, may provide important clues to the neuronal conditions favoring Lewy body formation.
Although the majority of previous studies have reported that ␣-synuclein is restricted to axon terminals (9, 21, 23, 25, 26) , there are some exceptions. Maroteaux and Scheller found both synaptic and nuclear expression of this protein in Torpedo electric organ and CA3 of rat brain (47) . Consistent with our findings, a few recent studies identify perikaryal expression of ␣-synuclein in some brain regions. Perikaryal ␣-synuclein was observed in occasional somata of SNc of ␣-synuclein overexpressing mice, but not in controls (4, 48) . In addition, Giasson et al reported abundant presence of ␣-synuclein in medullary neurons including raphe, hypoglossal nucleus, dorsal vagal motor nucleus, and arcuate nucleus in cases of progressive supranuclear palsy and PD (32) . However, the authors raise the possibility that the cellular ␣-synuclein expression could be an abnormality of the disease state. The possibility of glia along the deep layer VIcallosal interface containing ␣-synuclein is interesting in light of the identification of ␣-synuclein inclusions in white matter oligodendrocytes in multiple system atrophy (14-16), although ␣-synuclein-containing glia have not previously been detected in normal brain tissue. Confirmation of this suggestion awaits double labeling histology. Variability in ␣-synuclein cellular expression has been attributed also to developmental changes. Perikaryal distribution of ␣-synuclein was detected in human embryonic brain tissue at gestational age 15 weeks, but redistribution from somata to processes occurred by gestational age 18 weeks (31). In contrast with our findings, these investigators do not find cellular expression of ␣-synuclein in adult substantia nigra. Most recently, it has been shown that pretreatment of brain sections with either Proteinase K or formic acid revealed perikaryal ␣-synuclein staining that was otherwise undetectable in human brain tissue and that the distribution coincides with the distribution of Lewy bodies in LBD (49) .
In addition to antibody differences, another source of variability noted in the present study was rostral to caudal variation. For example, ␣-synuclein expression in the pyramidal layers of dorsal hippocampus was found to be exclusively presynaptic, a finding consistent with previous work (9) . However, following the hippocampus caudal and ventral into the temporal lobe, ␣-synuclein staining was detected in somata and dendrites of the pyramidal neurons. Additionally, cellular expression of ␣-synuclein was greater in the ventrocaudal dentate gyrus than in the dorsal region of this structure. Thus, regional variability of ␣-synuclein expression within a brain structure may also explain some differences among reports.
The present results differ from the generally accepted findings of ␣-synuclein distribution. Furthermore, there was variability within our own findings of ␣-synuclein expression in rat midbrain in the results obtained from the 3 antibodies used. Under optimal immunohistochemical conditions, the polyclonal antibodies identified scarce neurons of SNc and VTA expressing somal ␣-synuclein. Therefore, it is clear that there are differences among antibodies that are likely to contribute to conflicting reports of the pattern of ␣-synuclein distribution. These differences demonstrate the caution with which it is necessary to interpret immunohistochemical results. Since the Syn-1 mAB was used for the extensive rat brain mapping and it recognized a novel pattern of ␣-synuclein distribution, great care was taken to validate the specificity of this mAB. ␣-Synuclein from rat brain lysate migrated at a single 17-kDa band under strong denaturing/reducing conditions, although there is evidence for higher molecular weight species under milder extraction conditions. In SH-SY5Y cell lysate, the Syn-1 antibody recognizes 2 migration bands; the higher molecular weight species can be broken down under stringent extraction conditions yielding a quantitative increase in the monomer (29) . Therefore, the heavier species has been shown to be a multimer containing at least 1 ␣-synuclein molecule. Selectivity of the Syn-1 mAB was further demonstrated by the complete abolition of Syn-1 immunoreactivity in the negative tissue controls and the failure to alter the pattern of the mAB reaction in the positive tissue controls. The absence of Syn-1 cross-reactivity with ␤-or ␥-synuclein was demonstrated also in vitro by Western blot and ELISA. Thus, cross-reaction with ␤-or ␥-synuclein cannot account for the ␣-synuclein distribution found in this study. Finally, no Syn-1 immunoreactivity is observed in ␣-synuclein null mice (L. Stefanis, personal communication). Taken together, the results indicate that the Syn-1 mAB is highly selective and specific for ␣-synuclein.
While epitope binding site and affinity are generally understood to be important in antibody recognition of protein, molecular configuration of the target protein may contribute also to differences in recognition among antibodies. We previously reported that ␣-synuclein interconverts between at least 2 physiological species, a soluble monomer and a lipid-associated oligomer (29) . Two similar forms of ␣-synuclein have been identified in vitro, a soluble monomer with little secondary structure and a phospholipid-bound form that adopts an ␣-helical configuration (50, 51) . At least some antibodies that recognize the N-and C-terminus of ␣-synuclein do not detect the endogenous ␣-synuclein oligomer in SH-SY5Y cells (Julia George, personal communication). Thus, differences in the state of ␣-synuclein such as conformation, solubility, and intermolecular structure may affect its affinity for various antibodies. The differences in antibody recognition of the multiple endogenous forms of ␣-synuclein could provide valuable insight into determining whether various forms of this protein are differentially vulnerable to aggregation and neurotoxicity.
